AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology
company developing a new generation of human enzyme therapeutics as
innovative solutions for rare and other high burden diseases, today
announced the appointment of Alison
Lawton to its Board of Directors. Ms. Lawton previously
served as president and CEO of Kaleido Biosciences.
"We are pleased to welcome Alison to the Aeglea Board at this
pivotal stage of the company's growth. As we move closer to
becoming a commercial-ready company, it is important to have a
breadth of experience and diversity of perspective to help shape
our strategy and accelerate our progress," said Anthony Quinn, M.B Ch.B, Ph.D., president and
chief executive officer of Aeglea. "We believe that this addition
complements our Board's skills and experiences and strengthens our
ability to bring impactful medicines to people living with rare
metabolic disorders."
"This is an exciting time to be joining Aeglea with a late-stage
human enzyme therapeutic being investigated to treat Arginase 1
Deficiency and a second, clinic-ready program for Homocystinuria,"
said Ms. Lawton. "I look forward to working with the leadership
team to advance these clinical programs and support additional
candidates emerging from the Company's human enzyme therapeutics
platform to make a positive impact for patients in need."
Ms. Lawton is an executive leader with more than 30 years of
experience in biopharma. Prior to Kaleido Biosciences,
Ms. Lawton served as chief operating officer of Aura Biosciences
and OvaScience and worked at various positions of increasing
responsibility at Genzyme, and subsequently at Sanofi-Aventis,
including as head of Genzyme Biosurgery and prior senior vice
president of Global Market Access. Ms. Lawton currently serves as
independent director for X4 Pharmaceuticals and ProQR Therapeutics
and has served on the Boards of Directors of Verastem, CoLucid
until its acquisition by Eli Lilly, and Cubist Pharmaceuticals
until its acquisition by Merck & Co. She is past president and
chair of the Board of Regulatory Affairs Professional Society and
past FDA Advisory Committee member for Cell and Gene Therapy
Committee. She earned her BSc in Pharmacology, with honors, from
King's College London.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare and other high burden diseases. Aeglea's lead
product candidate, pegzilarginase, is in a pivotal Phase 3 trial
for the treatment of Arginase 1 Deficiency and has received both
Rare Pediatric Disease and Breakthrough Therapy Designation. In the
second quarter of 2020, the Company initiated a Phase 1/2 clinical
trial of ACN00177 for the treatment of Homocystinuria. ACN00177 has
also been granted Rare Pediatric Disease Designation. Aeglea has an
active discovery platform, with the most advanced program for
Cystinuria. For more information, please visit
http://aegleabio.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, statements we
make regarding the potential addressable markets of our product
candidates, the timing and success of our clinical trials and
related data, the timing and expectations for regulatory
submissions and approvals, timing and results of meetings with
regulators, the timing of announcements and updates relating to our
clinical trials and related data, our ability to enroll patients
into our clinical trials, the expected impact of the COVID-19
pandemic on our operations and clinical trials, success in our
collaborations, our cash forecasts, and the potential
therapeutic benefits and economic value of our lead product
candidate or other product candidates. Further information on
potential risk factors that could affect our business and its
financial results are detailed in our most recent Quarterly Report
on Form 10-Q for the quarter ended September
30, 2020 filed with the Securities and Exchange Commission
(SEC), and other reports as filed with the SEC. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-appoints-alison-lawton-to-board-of-directors-301195568.html
SOURCE Aeglea BioTherapeutics, Inc.